ATE440103T1 - Mannose-6-phosphonat-verbindungen zur behandlung von entzündungskrankheiten - Google Patents

Mannose-6-phosphonat-verbindungen zur behandlung von entzündungskrankheiten

Info

Publication number: ATE440103T1
Authority: AT; Austria
Prior art keywords: compounds; mannose; treatment; migration; inflammatory diseases
Prior art date: 2003-05-20

Application number

AT04752819T

Other languages

English (en)

Inventor

William Cowden

Gavin Bartell

Darren March

Alan Robertson

Bart Eschler

Original Assignee

Pharmaxis Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-20

Filing date

2004-05-20

Publication date

2009-09-15

2004-05-20 Application filed by Pharmaxis Pty Ltd filed Critical Pharmaxis Pty Ltd

2009-09-15 Application granted granted Critical

2009-09-15 Publication of ATE440103T1 publication Critical patent/ATE440103T1/de

Links

208000027866 inflammatory disease Diseases 0.000 title 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 3
230000005012 migration Effects 0.000 abstract 3
238000013508 migration Methods 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 abstract 1
201000004624 Dermatitis Diseases 0.000 abstract 1
208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
102000001696 Mannosidases Human genes 0.000 abstract 1
108010054377 Mannosidases Proteins 0.000 abstract 1
HOGAGKVTOGTBKP-UHFFFAOYSA-N O=P(=O)C1CCCCO1 Chemical class O=P(=O)C1CCCCO1 HOGAGKVTOGTBKP-UHFFFAOYSA-N 0.000 abstract 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 abstract 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
206010046851 Uveitis Diseases 0.000 abstract 1
208000002552 acute disseminated encephalomyelitis Diseases 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000003278 mimic effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
208000001050 sialadenitis Diseases 0.000 abstract 1
208000025889 stromal keratitis Diseases 0.000 abstract 1
206010043778 thyroiditis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
- C07H11/04—Phosphates; Phosphites; Polyphosphates

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pain & Pain Management (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT04752819T 2003-05-20 2004-05-20 Mannose-6-phosphonat-verbindungen zur behandlung von entzündungskrankheiten ATE440103T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47171603P	2003-05-20	2003-05-20
PCT/US2004/015876 WO2004104015A2 (en)	2003-05-20	2004-05-20	Mannose-6-phosphonate compounds for the treatment of inflammatory diseases

Publications (1)

Publication Number	Publication Date
ATE440103T1 true ATE440103T1 (de)	2009-09-15

Family

ID=33476877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04752819T ATE440103T1 (de)	2003-05-20	2004-05-20	Mannose-6-phosphonat-verbindungen zur behandlung von entzündungskrankheiten

Country Status (12)

Country	Link
US (1)	US7648966B2 (de)
EP (1)	EP1628987B1 (de)
AT (1)	ATE440103T1 (de)
AU (1)	AU2004240938B2 (de)
CA (1)	CA2525328C (de)
DE (1)	DE602004022659D1 (de)
DK (1)	DK1628987T3 (de)
ES (1)	ES2330004T3 (de)
NZ (1)	NZ544085A (de)
PL (1)	PL1628987T3 (de)
PT (1)	PT1628987E (de)
WO (1)	WO2004104015A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2930942B1 (fr) *	2008-05-07	2011-03-04	Centre Nat Rech Scient	Nouvelles utilisations de derives de d-mannopyranose activateurs de l'angiogenese
US8557783B2 (en)	2009-04-28	2013-10-15	Pharmaxis Pty Limited	Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders
AU2019404061A1 (en)	2018-12-19	2021-07-22	The Board Of Trustees Of The Leland Stanford Junior University	Bifunctional molecules for lysosomal targeting and related compositions and methods
EP4370157A1 (de)	2021-07-14	2024-05-22	Lycia Therapeutics, Inc.	Verbindungen und konjugate zur bindung des aspr-zelloberflächenrezeptors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1985005031A1 (en) *	1984-05-09	1985-11-21	The Australian National University	A method for the modulation of the immune response
US6140301A (en) *	1995-04-27	2000-10-31	The Procter & Gamble Company	Process for producing granular detergent components or compositions
GB9516012D0 (en)	1995-08-04	1995-10-04	Univ Manchester	Pharmaceutical composition
AU728393B2 (en)	1996-10-18	2001-01-11	Australian National University, The	Novel phosphosugars and phosphosugar-containing compounds having anti-inflammatory activity
AUPQ872300A0 (en)	2000-07-11	2000-08-03	Praxis Pharmaceuticals Pty Ltd	Compounds and methods

2004
- 2004-05-20 ES ES04752819T patent/ES2330004T3/es not_active Expired - Lifetime
- 2004-05-20 EP EP04752819A patent/EP1628987B1/de not_active Expired - Lifetime
- 2004-05-20 AT AT04752819T patent/ATE440103T1/de active
- 2004-05-20 DE DE602004022659T patent/DE602004022659D1/de not_active Expired - Lifetime
- 2004-05-20 AU AU2004240938A patent/AU2004240938B2/en not_active Ceased
- 2004-05-20 WO PCT/US2004/015876 patent/WO2004104015A2/en not_active Ceased
- 2004-05-20 NZ NZ544085A patent/NZ544085A/en not_active IP Right Cessation
- 2004-05-20 PL PL04752819T patent/PL1628987T3/pl unknown
- 2004-05-20 DK DK04752819T patent/DK1628987T3/da active
- 2004-05-20 CA CA2525328A patent/CA2525328C/en not_active Expired - Fee Related
- 2004-05-20 PT PT04752819T patent/PT1628987E/pt unknown
- 2004-05-20 US US10/557,773 patent/US7648966B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7648966B2 (en)	2010-01-19
AU2004240938B2 (en)	2009-11-19
WO2004104015A8 (en)	2005-05-26
CA2525328C (en)	2012-07-31
DE602004022659D1 (de)	2009-10-01
NZ544085A (en)	2008-10-31
WO2004104015A2 (en)	2004-12-02
ES2330004T3 (es)	2009-12-03
AU2004240938A1 (en)	2004-12-02
PT1628987E (pt)	2009-10-29
WO2004104015A3 (en)	2005-03-24
DK1628987T3 (da)	2009-12-21
EP1628987A2 (de)	2006-03-01
EP1628987B1 (de)	2009-08-19
PL1628987T3 (pl)	2010-01-29
CA2525328A1 (en)	2004-12-02
US20070082850A1 (en)	2007-04-12

Similar Documents

Publication	Publication Date	Title
Magaudda et al.	2006	Unverricht‐Lundborg disease, a condition with self‐limited progression: long‐term follow‐up of 20 patients
Krystal et al.	1999	SHIPs ahoy
EA200602191A1 (ru)	2007-06-29	5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
DE69328778D1 (de)	2000-07-06	Verbindungen für die behandlung von entzündlichen erkrankungen und zur hemmung der produktion von tumornekrosefaktor
BR9811599A (pt)	2000-09-19	Compostos de dipetìdeo que inibem adesão de leucócito mediada por vla-4
EP1673078A4 (de)	2007-04-18	Benzylether- und benzylamino-beta-sekretase-hemmer zur behandlung von alzheimer-krankheit
MA27675A1 (fr)	2005-12-01	Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
ATE544748T1 (de)	2012-02-15	Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
BRPI0410454A (pt)	2006-06-13	composições e compostos imunossupressores
EA200601239A1 (ru)	2007-02-27	Замещённые хинолиновые соединения
EA200501710A1 (ru)	2006-06-30	Замещённые карбоновые кислоты
ATE460413T1 (de)	2010-03-15	Substituierte 1-propinoyl-piperazine mit affinität für den mglur5 rezeptor zur behandlung von schmerzzuständen
NO20052272L (no)	2005-06-06	CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
ATE260653T1 (de)	2004-03-15	Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
MA28241A1 (fr)	2006-10-02	Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer
EA200100342A1 (ru)	2001-10-22	Связывающие соединения адгезионной молекулы нервной клетки
ATE440103T1 (de)	2009-09-15	Mannose-6-phosphonat-verbindungen zur behandlung von entzündungskrankheiten
ATE290857T1 (de)	2005-04-15	Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE538796T1 (de)	2012-01-15	Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
EA200601607A1 (ru)	2007-02-27	Сульфонамидные соединения для лечения нейродегенеративных расстройств
ATE435649T1 (de)	2009-07-15	4-brom-5-(2-chlor-benzoylamino)-1h-pyrazol-3- carbonsäure(phenyl)amid-derivate und verwandte verbindungen als bradykinin b1 receptor antagonisten zur behandlung von entzündlichen erkrankungen
Dan et al.	2004	From electrophysiology to chromatin: a bottom‐up approach to Angelman syndrome
MX2024006740A (es)	2024-06-19	Composiciones y metodos para modular la expresion de apoc3.
Álvarez et al.	2023	POS0135 GENETICAL AND PHENOTYPICAL FINDINGS OF CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS
WO2003026404A3 (en)	2003-12-04	Ccr6 chemokine receptor disruptions, compositions and methods relating thereto

Legal Events

Date

Code

Title

Description

2010-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1628987

Country of ref document: EP